

University of Dundee

Vitamin K supplementation to improve vascular stiffness in CKD

Witham, Miles; Lees, Jennifer S.; White, Myra; Band, Margaret; Bell, Samira; Chantler, Donna J.

Published in:
Journal of the American Society of Nephrology

DOI:
[10.1681/ASN.2020020225](https://doi.org/10.1681/ASN.2020020225)

Publication date:
2020

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Witham, M., Lees, J. S., White, M., Band, M., Bell, S., Chantler, D. J., Ford, I., Fulton, R., Kennedy, G., Littleford, R., McCrea, I. V., McGlynn, D., Panarelli, M., Ralston, M. R., Rutherford, E., Severn, A., Thomson, N., Traynor, J. P., Struthers, A. D., ... Mark, P. B. (2020). Vitamin K supplementation to improve vascular stiffness in CKD: The K4Kidneys randomized controlled trial. *Journal of the American Society of Nephrology*, 31(10), 2434-2445. <https://doi.org/10.1681/ASN.2020020225>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Supplemental Material

Contents

- 1. Details of assays used in the K4Kidneys trial**
- 2. Details of studies included in the meta-analysis**
 - 3. Time to first fall**
 - 4. Vascular calcification results**
- 5. Forest plots for vascular calcification**

1. Supplementary Table: Details of assays used in the trial

Assay	Manufacturer	Coefficient of variation	
		Intra-assay	Inter-assay
Fetuin A	R+D Systems Quantikine ELISA	3.5-4.2%	8.5-8.8%
Fibroblast Growth Factor 23	Immutopics C-terminal ELISA	3.3-11.5%	3.3-11.5%
Osteocalcin	R+D Systems Quantikine ELISA	5.2-5.4%	7.3-13.8%
Insulin	Alpco ELISA	4.8-6.9%	4.9-13.5%
25-hydroxyvitamin D	Diasorin LIAISON	2.9-8.4%	5.6-10.1%
1,25 dihydroxyvitamin D	Diasorin LIAISON XL	5.3-8.4%	8.2-8.8%
dp-ucMGP	IDS-iSYS InaKtif MGP	≤ 5.0% (between 910 and 7312 pmol/L)	≤ 7.3% between 939 and 7386 pmol/L)
Tartrate-resistant acid phosphatase-5b	Cusabio ELISA	6.9%	6.3-14.3%
N-terminal pro B-type natriuretic peptide	Meso Scale Discovery ELISA	8.0%	13.2-15.5%


dp-ucMGP: desphospho-uncarboxylated matrix Gla protein

*A threshold of 900 pmol/L was used as the lowest reportable concentration of dp-ucMGP. Assay performance below this concentration was found to be non-linear on dilution testing, thus values below 900 pmol/L cannot be reported with accuracy.

2. Supplementary Table: Details of studies included in the meta-analysis

Author	Year	Country	Baseline N	Population	Intervention	Dose (mcg/day)	Comparator	Duration (months)	Outcome measure
Braam ³³	2004	Netherlands	121	Healthy	K1 +Multivitamin (incl vitamin D)	1000	Multivitamin (incl vitamin D)	36	Compliance coefficient (mm ² /kPa)
Shea ³⁴	2009	USA	295	Older adults	K1 +Multivitamin (incl vitamin D)	500	Multivitamin (incl vitamin D)	36	Coronary artery calcification score
Knapen ³⁵	2015	Netherlands	244	Postmenopausal women	K2-MK7	180	Placebo	36	Pulse wave velocity (SphygmoCor)
Kurnatowska ¹⁶	2015	Poland	40	CKD	K2-MK7 + Vitamin D	90	Vitamin D	9	Coronary artery calcification score
Fulton ¹⁸	2016	Scotland	80	Older adults, vascular disease	K2-MK7	100	Placebo	6	Pulse wave velocity (SphygmoCor)
Brandenburg ³⁶	2017	Germany	72	Aortic stenosis or sclerosis	K1	2000	Placebo	12	Aortic valve calcification score
Oikonomaki ³⁷	2019	Greece	102	Patients undergoing haemodialysis	K2-MK7	200	Usual care	12	Abdominal aortic calcification score
Zwakenberg ³⁹	2019	Netherlands	68	Patients with type 2 diabetes mellitus	K2-MK7	360	Placebo	6	Femoral artery calcification score
De Vriese ³⁸	2020	Belgium	88	Patients undergoing haemodialysis with atrial fibrillation	K2-MK7 + Rivaroxaban	857	Rivaroxaban	18	Coronary artery calcification score

3. Supplementary Figure. Time to first fall




Time to first fall: HR 0.79 (95% CI 0.37 to 1.69, p=0.54)

4. Vascular calcification results

	Vitamin K Mean (SD)	Placebo Mean (SD)	Treatment effect* (95% CI)	p
Mean Aortic calcification score (SD) at 12 months	4.8 (5.1)	4.2 (5.3)	-0.3 (-0.8 to 0.2)	0.31
[Median (Q1,Q3)]	[3 (0,8)]	[3 (0,5)]		
Mean Aortic calcification score (SD) at 12 months (excluding zero scores)	7.0 (4.8)	6.5 (5.3)	-0.3 (-1.1. to 0.42)	0.37
Change in aortic calcification score between baseline and 12 months (SD)	0.0 (1.4)	0.3 (1.4)	-0.3 (-0.8 to 0.2)	0.31
No detectable calcification at baseline (%)	18 (30.0)	22 (36.7)	Odds ratio 0.2 (0.0 to 4.3)	0.30
No detectable calcification at 12 months (%)	19 (31.7)	21 (35.6)		

5. Forest plots – vascular calcification

a) Excluding current trial



b) Including current trial

